After more than 30 years of practice, recent findings in lung cancer treatment are opening a new era. Conducted by MSD, also known as Merck in the U.S. and Canada, the study known as KEYNOTE-024 (KN-024) suggests that the immunotherapy drug pembrolizumab stands as a possible first-line treatment for non-small cell lung cancer (NSCLC) to replace chemotherapy.
